Craig Asher

mcPCR: methyl copying PCR. mcPCR is our novel and proprietary platform technology that preserves DNA methylation during DNA amplification. The method is analogous to traditional PCR, which efficiently and accurately copies the four-base code of DNA. But PCR cannot amplify the 5mC signal. By overcoming this fundamental limitation, mcPCR copies the original DNA methylation patterns and the underlying four-base code. This will enable simpler, faster and more sensitive analysis of methylated DNA even from the most limiting of clinical samples.

With the power to skillfully write meaningful DNA sequences, we embark on a new era where precise control over biology and the manipulation of matter in our environment is possible. Constructive Biology is a spin out from the laboratory of Prof. Jason Chin at the MRC Laboratory of Molecular Biology in Cambridge. Our platform allow us to fundamentally reprogram the genetic code, and make molecules that nature could not make before. We will use our technologies to biosynthesize new classes of enzymes, pharmaceuticals and biomaterials. If you would like to join our team, get in touch!

Replay is a genome writing company, which aims to define the future of genomic medicine through reprogramming biology by writing and delivering big DNA. The Company has assembled a toolkit of disruptive platform technologies – including a high payload capacity HSV platform, a hypoimmunogenic platform, and a genome writing platform – to address the scientific challenges currently limiting clinical progress and preventing genomic medicine from realising its full potential. The Company’s hub-and-spoke business model separates technology development within Replay from therapeutic development in product companies, which leverage the technology platforms. For example, Replay’s synHSV™ technology, a high payload capacity HSV vector capable of delivering up to 30 times the payload of AAV, is utilized by Replay’s four gene therapy product companies, bringing big DNA treatments to diseases affecting the skin, eye, brain, and muscle. The Company has, additionally, established an enzyme writing product company engaging its evolutionary inference machine learning and genome writing technology to optimize functionality. Replay is led by a world-class team of academics, entrepreneurs and industry experts.

Aperiam is building hyperfolding enzymes with deep learning algorithms that understand protein chemistry.

Veda is derived from the Sanskrit word for the creation of knowledge. With our team of industry leading experts, we operate at the forefront of scientific innovation to push the limits of what’s possible in the field of molecular detection. VedaBio is unlocking a universe of possibilities in molecular biology with a breakthrough platform for near-instant molecular detection of highly multiplexed analytes, delivering best-in-class accuracy without the need for target amplification.

We sequence proteins. Glyphic Biotechnologies is a biotechnology startup revolutionizing the field of proteomics. While DNA can reveal biological insights, proteins actually tell us what our bodies will do. We are developing a first-of-its-kind, next-generation protein sequencing platform to enable researchers to gain novel insights into biology and disease.

Lightcast is developing a novel, droplet-based platform that provides a deeper understanding of cellular function. Compared to standard microfluidic methods, the Lightcast platform offers the ability to run a broader range of assays and to precisely control and track the number, occupancy, location, and movement of each droplet. The unprecedented scalability and flexibility of this approach will help advance translational and basic research as well as streamline development workflows for drugs, therapeutics, and applied biologics.

Our Gene Writing™ technology advances genetic medicine beyond its current limitations. Learn more at http://TesseraTherapeutics.com

Matterworks is using the power of AI to fundamentally change the impact of biological measurements and observations.

Tasso is a fast-growing Seattle-based startup focused on delivering at-home diagnostic testing to those who need it most. We are growing our footprint with leading health systems, clinical research organizations, academic medical centers, and more who are looking to deliver clinical-grade, convenient diagnostic tests to their patients. Tasso was originally founded to find a better way to collect blood instead of a painful fingerstick or time-consuming venous draw. Since then, our products have been used in pharmaceutical clinical trials, by Olympians as part of a new virtual anti-doping program, and broadly by hospital systems across the US.

We are accelerating drug discovery to deliver treatments to patients faster. Our powerful engine integrates combinatorial chemistry, pico-scale activity-based screening, and AI, generating millions of empirical datapoints every week to evolve our models. This enables our biologists and medicinal chemists to discover novel small molecule therapeutics rapidly.

Mythic Therapeutics is a product-platform company that is pioneering a powerful new approach to improving the effectiveness of antibody-drug conjugates (ADCs) and other antibody-based therapeutics. Our technology dramatically increases therapeutic potency without compromising safety, thereby unlocking the full potential of targeted therapies against a broad array of tumor targets. At Mythic, we focus on patient-centered science and are driven to leave a lasting impact on cancer care.

We're excited to be part of the larger team at Inscripta, Inc! You can visit us at www.inscripta.com and learn more about the acquisition at https://www.inscripta.com/news/inscripta-acquires-infinome-biosciences-and-sestina-bio

We are Compass Pathways, a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Our first clinical development programme is researching investigational COMP360 psilocybin treatment for patients with treatment-resistant depression. We want to transform the patient experience in mental health care.

Delix Therapeutics is applying modern tools of pharmaceutical development to some of natures most ancient therapies, psychedelics. Through its discovery platform, Delix has identified a new class of non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. Delix is rapidly advancing these psychoplastogen compounds through preclinical and clinical development, with the goal of one day alleviating mental suffering through its FDA-approved, take-home medicines.

mcPCR: methyl copying PCR. mcPCR is our novel and proprietary platform technology that preserves DNA methylation during DNA amplification. The method is analogous to traditional PCR, which efficiently and accurately copies the four-base code of DNA. But PCR cannot amplify the 5mC signal. By overcoming this fundamental limitation, mcPCR copies the original DNA methylation patterns and the underlying four-base code. This will enable simpler, faster and more sensitive analysis of methylated DNA even from the most limiting of clinical samples.

With the power to skillfully write meaningful DNA sequences, we embark on a new era where precise control over biology and the manipulation of matter in our environment is possible. Constructive Biology is a spin out from the laboratory of Prof. Jason Chin at the MRC Laboratory of Molecular Biology in Cambridge. Our platform allow us to fundamentally reprogram the genetic code, and make molecules that nature could not make before. We will use our technologies to biosynthesize new classes of enzymes, pharmaceuticals and biomaterials. If you would like to join our team, get in touch!

Replay is a genome writing company, which aims to define the future of genomic medicine through reprogramming biology by writing and delivering big DNA. The Company has assembled a toolkit of disruptive platform technologies – including a high payload capacity HSV platform, a hypoimmunogenic platform, and a genome writing platform – to address the scientific challenges currently limiting clinical progress and preventing genomic medicine from realising its full potential. The Company’s hub-and-spoke business model separates technology development within Replay from therapeutic development in product companies, which leverage the technology platforms. For example, Replay’s synHSV™ technology, a high payload capacity HSV vector capable of delivering up to 30 times the payload of AAV, is utilized by Replay’s four gene therapy product companies, bringing big DNA treatments to diseases affecting the skin, eye, brain, and muscle. The Company has, additionally, established an enzyme writing product company engaging its evolutionary inference machine learning and genome writing technology to optimize functionality. Replay is led by a world-class team of academics, entrepreneurs and industry experts.

Aperiam is building hyperfolding enzymes with deep learning algorithms that understand protein chemistry.

Veda is derived from the Sanskrit word for the creation of knowledge. With our team of industry leading experts, we operate at the forefront of scientific innovation to push the limits of what’s possible in the field of molecular detection. VedaBio is unlocking a universe of possibilities in molecular biology with a breakthrough platform for near-instant molecular detection of highly multiplexed analytes, delivering best-in-class accuracy without the need for target amplification.